secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0000950170-23-002808
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Q2 net loss $3.5M; cash $4.9M; VAL-083 gets orphan status for DIPG
--------------------------------------------------------------------------

- Net loss of $3.5M vs $5.9M YoY; diluted EPS -$2.10 vs -$6.07.
- Cash and equivalents $4.9M at Dec 31, 2022, down from $11.8M at June 30.
- FDA granted Orphan Drug Designation for VAL-083 in DIPG; Fast Track for REM-001 in CMBC.
- REM-001 program paused to conserve cash, expected savings of ~$3.0M through CY2023.
- Regained Nasdaq minimum bid price compliance after 1-for-50 reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/0000950170-23-002808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/ktra-20230214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer